港股異動 | 亞盛醫藥-B(6855.HK)漲約6% 5日累計反彈近40% 去年營收同比增123.2%
格隆匯3月22日丨亞盛醫藥-B(6855.HK)午後拉昇漲5.91%,5日累計反彈近40%。現報16.84港元,暫成交3823萬港元,總市值45億港元。公司昨晚公佈,2021年實現收入2791萬元,同比增長123.2%。公司業績主要來自首個商業化產品的銷售、商業化許可費收入及專利知識產權許可費收入。公司現金流獲得持續改善,於2021年完成配售增發股份募得資金人民幣13億元。另外,公司APG-115獲美國FDA兒童罕見病資格認證,用於治療神經母細胞瘤。目前APG-115已獲得FDA授予的六項孤兒藥資格認證(ODD)、兩項RPD。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.